Stock Watch: Biogen, Blood In The Water
The Acquisition Targets Of A Company In Trouble May Not Be Enthusiastic
When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: J&J considers bold M&A moves; a prominent new CEO for Galapagos; Biogen’s interim leader talks to Scrip; a view on Biogen and M&A; and a look at Astellas’ digital shift plans.
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
The pharmaceutical sector is often unfairly demonized in the drug pricing debate. Other participants exploit the complex US health care system almost with impunity.